Geneseq Biosciences was founded in 2017 by Ryan Van Laar Ph.D, a translational genomics scientist with over 15 years of experience in designing, validating and performing clinically useful tests for cancer diagnosis, prognosis and treatment optimisation.
Dr Van Laar has over 20 peer-reviewed publications and has been involved in three successful FDA applications for novel genomic assays. A prior start-up, ChipDX.com, was acquired by Signal Genetics (New York) in 2012. Before founding Geneseq Biosciences, he was a VP of Research and Operations and Laboratory Director, based in Little Rock, AR, USA.
The company was co-founded by Barton Van Laar, a business strategy, marketing and communications specialist with extensive cross-sector experience.
Geneseq values the contributions of our commercial partners: